<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79110">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146846</url>
  </required_header>
  <id_info>
    <org_study_id>Kerman-001-FOPPT</org_study_id>
    <nct_id>NCT02146846</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Imatinib in CML Patients in Iran</brief_title>
  <official_title>Population Pharmacokinetics of Imatinib in CML Patients in Iran</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kerman University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kerman University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine population Pharmacokinetics and differences and
      variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in
      treatment of chronic myeloid leukemia patients in Iranian population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in
      this study then population pharmacokinetics parameters is determined.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percent of changes of AUC, trough Concentration from predicted values</measure>
    <time_frame>Blood sampling are collected on atleast the 30th day of treatment  at the following time: 1 hour before the dose and 1 hour after the dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The influence of patients' characteristic on the pharmacokinetics of Imatinib will be assessd.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Imatinib, CML</arm_group_label>
    <description>Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Patients with chronic myeloid leukemia who receive Imatinib as treatment</description>
    <arm_group_label>Imatinib, CML</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with approved diagnosis of chronic myeloid leukemia taking Imatinib as treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient in chronic phase of myeloid leukemia

          -  no liver and renal failure

        Exclusion Criteria:

          -  multiple dug treatment

          -  previous treatment of interferon

          -  patients in blast or accelerated phase
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ehsan mohajeri, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of pharmaceutics, Faculty of pharmacy, Kerman University of medical sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid-Bahonar hospital</name>
      <address>
        <city>Kerman</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kerman University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ehsan Mohajeri</investigator_full_name>
    <investigator_title>Assistant of Pharmaceutics</investigator_title>
  </responsible_party>
  <keyword>cml</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
